Pharma BD Deal Intelligence
Mylan and Pfizer's Upjohn division combined in a Reverse Morris Trust transaction to form Viatris, a new company with pro forma revenues of $19-20 billion. The deal combined Mylan's global generics platform with Upjohn's established brands including Lipitor and Viagra.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Mylan N.V. / Upjohn Inc. (Pfizer) (this deal) | 2019 | $12.0B | 44 |
| Mylan N.V. / Meda AB | 2016 | $9.9B | 53 |
| Mylan N.V. / Renaissance Acquisition Holdings, LLC (topicals business) | 2016 | $1.0B | 40 |
| Mylan N.V. / Novartis AG (TOBI franchise) | 2018 | $463M | 38 |
| Mylan N.V. / Perrigo Company plc | 2015 | $26.0B | — |
| Thermo Fisher Scientific Inc. / Life Technologies Corporation | 2013 | $15.1B | 84 |
| Merck KGaA / Sigma-Aldrich Corporation | 2014 | $17.0B | 80 |
← Browse all deals · How we score deals
More: 2019 deals · Mylan N.V. deals · Multiple (undisclosed) deals